Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(4-[[bis(methylene)(4-methylphenyl)-lambda6-sulfanyl]oxy]phenoxy)hydrazine
0.1 mM, complete inhibition
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-phenyl-2-aminopropane
-
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
-
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
5% inhition at 0.001 mM
2-bromo-N-(2-morpholinoethyl)nicotinamide
-
2-bromo-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-N-(3-morpholinopropyl)nicotinamide
-
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
46% inhibition at 0.05 mM
2-phenyl-5H-indeno[1,2-d]pyrimidine
-
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-A: 4.99
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-A: 5.15
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-A: 4.5
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
12% inhibition at 0.01 mM
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
3% inhibition at 0.01 mM
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
23% inhibition at 0.01 mM
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H -pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
21% inhibition at 0.01 mM
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
12% inhibition at 0.01 mM
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-chloro-N-(2-morpholinoethyl)nicotinamide
-
4-chloro-N-(3-morpholinopropyl)nicotinamide
-
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[2-[4-(benzyloxy)phenoxy]hydrazino]butanenitrile
0.1 mM, 39% inhibition
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
-
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-bromo-N-(2-morpholinoethyl)nicotinamide
-
5-bromo-N-(3-morpholinopropyl)nicotinamide
-
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6,11-dihydro-5H-benzo[a]carbazole
-
6-chloro-N-(2-morpholinoethyl)nicotinamide
-
6-chloro-N-(3-morpholinopropyl)nicotinamide
-
6-fluoro-N-(2-morpholinoethyl)nicotinamide
-
6-fluoro-N-(3-morpholinopropyl)nicotinamide
-
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6-methyl-N-(2-morpholinoethyl)nicotinamide
-
6-methyl-N-(3-morpholinopropyl)nicotinamide
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 4.9
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.5
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.55
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-A: 6.35
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 5.26
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.73
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.0
Acetylcholine
competitively inhibits monoamine oxidase A in the brain in a tissue-dependent manner, inhibition of MAO-A in cerebellum
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-A: 5.02
D-amphetamine
reversible inhibitor
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-A by 44.2%
Harmaline
the ability of harmaline to modify the behavioral effects of 5-methoxy-N,N-dimethyltryptamine is mediated by the inhibition of MAOA. Serotonin2A receptors are responsible for the late hyperactivity induced by 5-methoxy-N,N-dimethyltryptamine in the presence of MAOA inhibitors
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(2-morpholinoethyl)nicotinamide
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-A: 5.34
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(3-morpholinopropyl)nicotinamide
-
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
-
N-(4-butoxybenzyl)-4-methylthioamphetamine
-
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-A
N-(4-methoxybenzyl)-4-methylthioamphetamine
-
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-A
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-phenyl-1H-indazole-5-carboxamide
-
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. As a reversible inhibitor it is selective towards rat liver MAO-A but the rate of irreversible inhibition of that enzyme is considerably slower
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
[4-(benzyloxy)phenoxy]hydrazine
0.1 mM, 43% inhibition
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
-
-
(2R)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
1% inhibition of isoform MAO-B at 0.01 mM, 14% inhibition of isoform MAO-A at 0.01 mM
(3E)-3-[2-(isopropylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
4% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
-
6%inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
-
13% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
-
10% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
-
2% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
17% inhibition of isoform MAO-B at 0.01 mM
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine
-
-
(R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
-
specific inhibitor of isoform MAO-B
1,4-diphenyl-2-butene
monoamine oxidase B
1-(1-methylhydrazino)-3-(phenylthio)propan-2-ol
-
-
1-(1-methylhydrazino)-3-[methyl(phenyl)amino]propan-2-ol
-
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-amino-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-phenyl-2-aminopropane
-
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1-methylhydrazine
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
29% inhibition at 0.05 mM
2,2-dibutyl-3-acetyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazoline
-
0.8 mM, 42.8% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,3,5-trifluoro-4-methoxybenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 82% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamid
-
1 mM, 72% inhibition
2,2-dibutyl-5-(4-chlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 59% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(furan-2-yl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 73% inhibition
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
12% inhibition at 0.001 mM
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
selective for MAO-B
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
-
-
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-ethylaminobenzylamine dihydrochloride
-
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-methylaminobenzylamine dihydrochloride
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
-
2-phenyl-5H-indeno[1,2-d]pyrimidine
37% inhibition at 0.02 mM
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
-
-
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
-
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-B: 7.57
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-B: 6.34
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-B: 5.49
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
17% inhibition at 0.01 mM
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
-
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
3-phenyl-4-(phenylseleno)isoquinoline
reversibly inhibits isoform MAO-B activity
3-phenyl-4-(phenylthio)isoquinoline
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[2-(ethylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
17% inhibition of isoform MAO-A at 0.01 mM
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
31% inhibition of isoform MAO-A at 0.01 mM
3-[[4-(trifluoromethyl)phenoxy]methyl]-5H-indeno[1,2-c]pyridazin-5-one
48% inhibition at 0.01 mM
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(4-fluorophenylseleno)-3-phenylisoquinoline
-
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
-
-
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
-
-
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
-
-
4-[(methylamino)carbonyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
9% inhibition of isoform MAO-B at 0.01 mM, 8% inhibition of isoform MAO-A at 0.01 mM
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2-chlorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
6,11-dihydro-5H-benzo[a]carbazole
38% inhibition at 0.025 mM
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-B: 8.29
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 6.95
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 6.06
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
-
-
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-B: 4.26
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-B: 8.18
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 5.56
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 7.4
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
8-(-3-chlorostyryl)-caffeine
by means of its dual action as A2A antagonist and MAO-B inhibitor 8-(-3-chlorostyryl)-caffeine reverses behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of Parkinson's disease
8-(3-chlorostyryl)caffeine
monoamine oxidase B
Acetylcholine
competitively inhibits monoamine oxidase B in the brain in a tissue-dependent manner, inhibition of MAO-B in basal ganglia
acridine
-
derivatives, irrevrsible inhibition, sensitivity of isozymes, overview
aminoguanidine
-
complete impairment of SSAO activity produced by aminoguanidine-treatment in obese rats is likely responsible for a weak limitation of fat deposition. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-B: 5.62
benzyl cyanide
-
reversible inhibitor
beta-phenylethylidenehydrazine
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
D-amphetamine
reversible inhibitor
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-B by 61.2%
Harmane
-
reversible enzyme-specific inhibitor
Iproniazid
-
nonselective inhibitor
isatin
reversible inhibitor
ladostigil
-
nonselective inhibitor
Mesobuthus gibbosus venom peptide
-
with specific MAO-A inhibitory activity, reversible, non-competitive, may be responsible for the anxiogenic effects of the scorpion venom on animals and humans
-
methylene blue
-
reversible enzyme-specific inhibitor
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-B: 4.5
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-B
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-B
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-phenyl-1H-indazole-5-carboxamide
-
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
NW 1772
-
specific inhibitor of isoform MAO-B
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
phentermine
reversible inhibitor
pirlindole mesylate
-
reversible enzyme-specific inhibitor
safinamide
reversible inhibitor of isoform MAO-B
selegilline
-
specific inhibitor of isoform MAO-B
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
selective for MAO-B
tetrindole mesylate
-
reversible enzyme-specific inhibitor
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
ZnSO4
-
1 mM, about 20% inhibition, monoamine oxidase A
[(E)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview
[(E)-N-bis-(2-propynyl)-2-(phenyl)ethyidene]hydrazine
synthesis and inhibition of MAO isozymes, overview
[(Z)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase A
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
monoamine oxidase B
Clorgyline
-
Clorgyline
MAOA-specific irreversible inhibitor, used clinically as antidepressant. It foms a covalent bond with FAD
Clorgyline
monoamine oxidase A
Clorgyline
addition of a 10fold molar excess of the acetylenic inhibitor clorgyline to rat MAO-A results in the formation of flavocyanine adduct
Clorgyline
addition of the MAO-A inhibitor caused an increase in the maximal levels of extracellular serotonin achieved when challenged with 3,4-methylenedioxymethamphetamine
Clorgyline
the reversible and selective MAO-A inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
Clorgyline
MAO-A forms a N(5) flavocyanine adduct on inhibition by clorgyline, MAO A is blocked at an N-terminal threonyl residue
Clorgyline
irreversible inhibitor of isoform MAO-A
isatin
-
isatin
reversible inhibitor
moclobemide
-
moclobemide
reversible inhibitor of isoform MAO-A
Pargyline
-
Pargyline
monoamine oxidase B
Pargyline
the irreversible and non-selective MAO inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
phentermine
-
phentermine
reversible inhibitor
rasagiline
-
beta-phenylethylidenehydrazine
a neuroprotective drug, inhibits MAO-A by 26.7%
beta-phenylethylidenehydrazine
a neuroprotective drug, inhibits MAO-B by 14.9%
chlorgyline
-
-
chlorgyline
-
specific inhibitor of isoform MAO-A
Clorgyline
-
-
Clorgyline
-
poor inhibition
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition
Deprenyl
-
Deprenyl
-
MAO-B sensitive
moclobemide
-
-
moclobemide
-
specific inhibitor of isoform MAO-A
Pargyline
-
-
Pargyline
-
irreversible inhibitor
Pargyline
-
MAO-B sensitive
Pargyline
-
irreversible inhibitor. Pargyline + semicarbazide-induced reduction of fat deposition results from decreased food intake and from impaired MAO and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines
Phenelzine
-
-
Phenelzine
-
the nonselective irreversible inhibitor of monoamine oxidase causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition
Phenelzine
weak inhibition of MAO-A
rasagiline
-
rasagiline
irreversible inhibitor of isoform MAO-B
rasagiline
specific MAO-B inhibitor
selegiline
-
-
selegiline
administration of the irreversible and selective MAO-B inhibitor selegiline does not produce any increase in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats, compared with the saline control
selegiline
irreversible inhibitor of isoform MAO-B
selegiline
specific MAO-B inhibitor
tranylcypromine
-
-
tranylcypromine
-
nonselective inhibitor
additional information
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
no inhibition: 1-thiocarbamoyl-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole, thiocarbamoyl-3-phenyl-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
alkylamino derivatives of 4-aminomethylpyridine, substrate-like, reversible inhibitors
-
additional information
alkylamino derivatives of 4-aminomethylpyridine, substrate-like, reversible inhibitors
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-A and MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-A and MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety
-
additional information
no inhibhition of MAO-A by selegiline
-
additional information
no inhibhition of MAO-A by selegiline
-
additional information
-
no inhibhition of MAO-A by selegiline
-
additional information
-
no inhibition of MAO-A by farnesol, chlorostyrylcaffeine, and 1,4-diphenyl-2-butene
-
additional information
no inhibition of MAO-A by farnesol, chlorostyrylcaffeine, and 1,4-diphenyl-2-butene
-
additional information
molecular docking of MAO-A and MAO-B, overview
-
additional information
-
inhibitors with a substitution at the 5-position in 2-[N-(2-propynyl) aminomethyl]-1-methyl indole
-
additional information
-
overview: selective inhibitors of form A and B
-
additional information
-
no inhibition by Mesobuthus gibbosus venom peptide
-
additional information
monoamine oxidase-B inhibitors and antiinflammatory agents might be effective in treating Alzheimers disease
-
additional information
monoamine oxidase-B inhibitors and antiinflammatory agents might be effective in treating Alzheimers disease
-
additional information
-
SSAO inhibition is not sufficient to impair fat deposition. Combined MAO and SSAO inhibition limits adiposity in non-obese as well as in obese rats
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety. No inhibition of MAOB by N-4-methoxybenzyl-(4-methylthioamphetamine) hydrochloride, N-4-butoxybenzyl-(4-methylthioamphetamine) hydrochloride, and N-4-benzyloxybenzyl-(4-methylthioamphetamine) hydrochloride
-
additional information
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety. No inhibition of MAOB by N-4-methoxybenzyl-(4-methylthioamphetamine) hydrochloride, N-4-butoxybenzyl-(4-methylthioamphetamine) hydrochloride, and N-4-benzyloxybenzyl-(4-methylthioamphetamine) hydrochloride
-
additional information
no inhibition of MAO-B by clorgyline
-
additional information
no inhibition of MAO-B by clorgyline
-
additional information
-
no inhibition of MAO-B by clorgyline
-
additional information
-
the enzyme is not inhibited by semicarbazide
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, overview
-
additional information
-
design, synthesis, and evaluation of selective MAO-B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[(m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4, overview
-
additional information
-
inhibitor binding affects the active site structures of MAO A and MAO B, overview
-
additional information
-
synthesis and molecular modeling of some hexahydroindazole derivatives as potent monoamine oxidase inhibitors, overview
-
additional information
-
isoform MAO-B is not inhibited by (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate, (3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate, (3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate, (3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate, (3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, moclobemide, 3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate, and 7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
additional information
-
not inhibited by farnesol, chlorostyrylcaffeine and 1,4-diphenyl-2-butene
-
additional information
not inhibited by farnesol, chlorostyrylcaffeine and 1,4-diphenyl-2-butene
-
additional information
3-phenyl-4-(phenyltelluro) isoquinoline does not inhibit 50% of the isoform MAO-B activity up to concentration of 0.1 mM
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0679
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.366
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.0445
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.33
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.03
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.302
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.098
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.326
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.402 - 0.49
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.2853 - 0.51
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0342 - 0.51
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0382 - 0.5
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.00496 - 0.485
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0067 - 0.53
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0638 - 0.513
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0523 - 0.501
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.63
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
Rattus norvegicus
-
0.0297
11H-indolo[3,2-c]cinnoline
Rattus norvegicus
pH 7.4, 37°C
0.00032 - 0.0085
2-bromo-N-(2-morpholinoethyl)nicotinamide
0.0019 - 0.035
2-bromo-N-(3-morpholinopropyl)nicotinamide
0.028 - 0.1
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
0.1
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
0.0018 - 0.0026
2-chloro-N-(2-morpholinoethyl)nicotinamide
0.0065 - 0.0094
2-chloro-N-(3-morpholinopropyl)nicotinamide
0.045 - 0.1
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.1
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.0471
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.018
2-phenyl-5H-indeno[1,2-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.0167
2-phenyl-9H-indeno[2,1-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.4874
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.19356
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.05522
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.20534
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.47019
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.06128
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.15
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.095
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.43
3-ethylamino-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.42
3-methylamino-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
2.2
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.0308
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.01
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.063
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.044
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.17
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.00075 - 0.074
4-chloro-N-(2-morpholinoethyl)nicotinamide
0.0075 - 0.053
4-chloro-N-(3-morpholinopropyl)nicotinamide
0.0216
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.10077
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.000084 - 0.048
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
0.0001 - 0.045
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
0.01339
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.03044
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.0299
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.00625
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.03724
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.0199
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.00834
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.026 - 0.055
5-bromo-N-(2-morpholinoethyl)nicotinamide
0.023 - 0.065
5-bromo-N-(3-morpholinopropyl)nicotinamide
0.000045 - 0.026
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.012 - 0.082
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.012
6,11-dihydro-5H-benzo[a]carbazole
Rattus norvegicus
pH 7.4, 37°C
0.00018 - 0.034
6-chloro-N-(2-morpholinoethyl)nicotinamide
0.00038 - 0.075
6-chloro-N-(3-morpholinopropyl)nicotinamide
0.015 - 0.1
6-fluoro-N-(2-morpholinoethyl)nicotinamide
0.08 - 0.1
6-fluoro-N-(3-morpholinopropyl)nicotinamide
0.00043 - 0.1
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.056 - 0.1
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.086 - 0.1
6-methyl-N-(2-morpholinoethyl)nicotinamide
0.1
6-methyl-N-(3-morpholinopropyl)nicotinamide
0.0003 - 0.00416
Clorgyline
10.7
moclobemide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.068 - 0.1
N-(2-morpholinoethyl)nicotinamide
0.01
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00174
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00188
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
1.69
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.1
N-(3-morpholinopropyl)nicotinamide
0.2459
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.43089
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.08991
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.19886
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.1859
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.47066
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.09053
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.01
N-phenyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.955
naringenin
Rattus norvegicus
-
580
safinamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.25
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.000036 - 0.0031
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
0.0042
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0000091
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000041
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000019
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000041
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000019
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000029
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000012
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000045
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000016
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000037
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0000098
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000034
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000011
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000015
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000011
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000007
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000024
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0002 - 0.00023
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
0.000016 - 0.00047
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
0.066
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
Rattus norvegicus
37°C, no preincubation
0.06
1-amino-3,4-dihydroquinolin-2(1H)-one
Rattus norvegicus
37°C, no preincubation
0.059
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.39
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.051
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.38
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.029
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.349
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.066
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.345
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
1
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
Rattus norvegicus
-
0.063
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
Rattus norvegicus
37°C, no preincubation
0.00004 - 0.1
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
0.000024 - 0.0005
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
0.00003 - 0.026
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.00005 - 0.07
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.002 - 0.1
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
0.001 - 0.0043
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.0094
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.038
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
Rattus norvegicus
pH 7.4, 37°C
0.013
2-phenyl-9H-indeno[2,1-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.0013 - 0.021
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
0.002 - 0.0265
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
0.000284 - 0.001
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
0.00009 - 0.0025
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
0.0004 - 0.0231
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
0.000015 - 0.0028
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
0.0002 - 0.008
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
0.00004 - 0.00144
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
0.0063 - 0.1
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
0.00053 - 0.00358
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00273 - 0.0028
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0029 - 0.00318
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0088 - 0.0707
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00127 - 0.00136
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
0.00027 - 0.002
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00042 - 0.0025
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0017 - 0.0026
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0011 - 0.0021
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
0.000912
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.00008
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.09856
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.25623
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50045
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.19844
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.09045
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47021
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.055
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.00251
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.07
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.09
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
Rattus norvegicus
-
0.03645
3-phenyl-4-(phenylseleno)isoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.07586
3-phenyl-4-(phenylthio)isoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.00631
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
Rattus norvegicus
pH 7.4, 37°C
2
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.0019
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.000409
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.00025 - 0.0318
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.08241
4-(4-fluorophenylseleno)-3-phenylisoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.000997 - 0.0033
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.000021 - 0.0044
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
0.000015 - 0.002
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.02
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.3
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.25
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.008 - 0.1
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
0.034
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.0036 - 0.1
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.00051 - 0.1
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
0.0001 - 0.0226
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
0.0017 - 0.0054
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.000111 - 0.0083
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.47045
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.49622
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47067
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48023
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50023
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48882
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50011
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47022
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.00002 - 0.0054
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
0.0018 - 0.1
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
0.0000128 - 0.0154
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
0.00046 - 0.026
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
0.000427
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.00112 - 0.0508
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
0.000013 - 0.006
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
0.0003 - 0.074
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
0.0038 - 0.091
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
0.000018 - 0.0135
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
0.0312 - 0.0931
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.105
Deprenyl
Rattus norvegicus
-
0.00047
fumarate
Rattus norvegicus
-
-
0.00759
iproniazid phosphate
Rattus norvegicus
pH and temperature not specified in the publication
-
0.0007
malate
Rattus norvegicus
-
-
0.01
moclobemide
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.01 - 0.1
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.00000382
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000132
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000143
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.0000225
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000565
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000889
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000221
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.708
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000236
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00136
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.005 - 0.1
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
0.01 - 0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
0.01 - 0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
0.26476
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.0999
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48055
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.19723
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.1842
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.09821
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47004
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.000708
N-phenyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.955
naringenin
Rattus norvegicus
-
0.00405
paragyline
Rattus norvegicus
-
0.018
safinamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00062
succinate
Rattus norvegicus
-
-
0.33
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.079
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.0201 - 0.0695
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00185
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
Rattus norvegicus
pH and temperature not specified in the publication
-
additional information
additional information
-
0.402
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.49
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.2853
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.499
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.51
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.0342
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.5
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.51
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.0382
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.486
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.5
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.00496
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.47
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.485
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.0067
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.5
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.53
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.0638
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.069
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.513
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.0523
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
preincubation 60 min, monoamine oxidase B
0.065
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase B
0.501
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
Rattus norvegicus
no preincubation, monoamine oxidase A
0.00032
2-bromo-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.0085
2-bromo-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.0019
2-bromo-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.035
2-bromo-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.028
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.1
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-A
0.1
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.0018
2-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.0026
2-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.0065
2-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.0094
2-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.045
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.1
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-A
0.1
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.00075
4-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.074
4-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.0075
4-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.053
4-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.000084
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.048
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.0001
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.045
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.026
5-bromo-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.055
5-bromo-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.023
5-bromo-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.065
5-bromo-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.000045
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.026
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.012
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.082
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.00018
6-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.034
6-chloro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.00038
6-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.075
6-chloro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-B
0.015
6-fluoro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
6-fluoro-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.08
6-fluoro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
6-fluoro-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.00043
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.056
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.086
6-methyl-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
6-methyl-N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.1
6-methyl-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-A
0.1
6-methyl-N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.0003
Clorgyline
Rattus norvegicus
-
0.00172
Clorgyline
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.00416
Clorgyline
Rattus norvegicus
monoamine oxidase A
0.068
N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
pH 7.4, 37°C, MAO-A
0.1
N-(2-morpholinoethyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.1
N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-A
0.1
N-(3-morpholinopropyl)nicotinamide
Rattus norvegicus
above, pH 7.4, 37°C, MAO-B
0.00272
Pargyline
Rattus norvegicus
-
0.00285
Pargyline
Rattus norvegicus
no preincubation, monoamine oxidase B
0.00405
Pargyline
Rattus norvegicus
no preincubation, monoamine oxidase B
0.39
Pargyline
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.000036
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
Rattus norvegicus
-
isoform MAO-B, pH and temperature not specified in the publication
0.0031
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0002
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00023
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.000016
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.00047
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00004
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000024
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0005
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00003
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.026
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00005
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.07
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.002
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.1
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.001
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0043
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0013
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.021
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.002
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0265
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000284
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
Rattus norvegicus
-
isoform MAO-B, pH and temperature not specified in the publication
0.001
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.00009
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0025
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0004
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0231
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000015
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0028
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0002
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.008
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00004
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.00144
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0063
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.1
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.00053
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.00358
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.00273
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.0028
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0029
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.00318
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0088
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0707
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.00127
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.00136
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.00027
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.002
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.00042
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0025
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.0017
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.0026
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0011
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.0021
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.00025
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0318
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000997
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0033
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-B, pH and temperature not specified in the publication
0.000021
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0044
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000015
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.002
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.008
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0036
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00051
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0001
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0226
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0017
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-B, pH and temperature not specified in the publication
0.0054
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000111
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0083
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-B, pH and temperature not specified in the publication
0.00002
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0054
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0018
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0000128
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0154
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00046
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.026
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.00112
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0508
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000013
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.006
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0003
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.074
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0038
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.091
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.000018
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.0135
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0312
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0931
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
0.01
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.005
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.01
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.01
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-B
0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
Rattus norvegicus
-
pH 7.4, temperature not specified in the publication, MAO-A
0.0201
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-A
0.0695
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
Rattus norvegicus
-
pH 7.6, 37°C, MAO-B
additional information
additional information
Rattus norvegicus
above 1.6 mM for 1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride, 3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride, and above 2.0 mM for 3-amino-4-aminomethylpyridine dihydrochloride. Above 0.1 mM for 3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate, 3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate, 3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate, and 3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
additional information
additional information
Rattus norvegicus
above 1.6 mM for 1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride, 3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride, and above 2.0 mM for 3-amino-4-aminomethylpyridine dihydrochloride. Above 0.1 mM for 3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate, 3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate, 3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate, and 3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
additional information
additional information
Rattus norvegicus
above 1.0 mM for 1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride, 3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride, 4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride, 1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride, 1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride, and above 0.17 mM for 4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride, 3-methylamino-4-aminomethylpyridine dihydrochloride, and 3-ethylamino-4-aminomethylpyridine dihydrochloride. Above 2.0 mM for 3-amino-4-aminomethylpyridine dihydrochloride and above 0.1 mM for 3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate, 3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate, 3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate, 3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate, 2-methylaminobenzylamine dihydrochloride, and 2-ethylaminobenzylamine dihydrochloride
-
additional information
additional information
Rattus norvegicus
above 1.0 mM for 1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride, 3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride, 4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride, 1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride, 1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride, and above 0.17 mM for 4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride, 3-methylamino-4-aminomethylpyridine dihydrochloride, and 3-ethylamino-4-aminomethylpyridine dihydrochloride. Above 2.0 mM for 3-amino-4-aminomethylpyridine dihydrochloride and above 0.1 mM for 3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate, 3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate, 3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate, 3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate, 2-methylaminobenzylamine dihydrochloride, and 2-ethylaminobenzylamine dihydrochloride
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Balsa, D.; Fernandez-Alverez, E.; Tipton, K.F.; Unzeta, M.
Monoamine oxidase inhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]-1-methyl indole derivatives
Biochem. Soc. Trans.
19
215-218
1991
Rattus norvegicus
brenda
Ma, J.; Ito, A.
Tyrosine residues near the FAD binding site are critical for FAD binding and for the maintenance of the stable and active conformation of rat monoamine oxidase A
J. Biochem.
131
107-111
2002
Rattus norvegicus, Rattus norvegicus MAO-A
brenda
Veryovkina, L.V.; Samed, M.M.A.; Gorkin, V.Z.
Mitochondrial monoamine oxidase of rat liver: reversible qualitative alterations in catalytic properties
Biochim. Biophys. Acta
258
56-70
1972
Rattus norvegicus
brenda
Tipton, K.F.; Spires, I.P.C.
The kinetics of phenethylhydrazine oxidation by monoamine oxidase
Biochem. J.
125
521-524
1971
Rattus norvegicus, Sus scrofa
brenda
Houslay, M.D.; Tipton, K.F.
A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes
Biochem. J.
139
645-652
1974
Rattus norvegicus
brenda
Dennick, R.G.; Mayer, R.J.
Purification and immunochemical characterization of monoamine oxidase from rat and human liver
Biochem. J.
161
167-174
1977
Homo sapiens, Rattus norvegicus
brenda
Stadt, M.A.; Banks, P.A.; Kobes, R.D.
Purification of rat liver monoamine oxidase by octyl glucoside extraction and reconstitution
Arch. Biochem. Biophys.
214
223-230
1982
Rattus norvegicus
brenda
McCauley, R.
Properties of a monoamine oxidase from rat liver mitochondrial outer membranes
Arch. Biochem. Biophys.
189
8-13
1978
Rattus norvegicus
brenda
Youdim, M.B.H.; Tenne, M.
Assay and purification of liver monoamine oxidase
Methods Enzymol.
142
617-627
1987
Rattus norvegicus
brenda
Hirashiki, I.; Ogata, F.; Ito, A.
Rat monoamine oxidase B expressed in Escherichia coli has a covalently-bound FAD
Biochem. Mol. Biol. Int.
37
39-44
1995
Rattus norvegicus
brenda
Hiro, I.; Tsugeno, Y.; Hirashiki, I.; Ogata, F.; Ito, A.
Characterization of rat monoamine oxidase A with noncovalently-bound FAD expressed in yeast cells
J. Biochem.
120
759-765
1996
Rattus norvegicus
brenda
Ma, J.; Kubota, F.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T.
Crystallization and preliminary crystallographic analysis of rat monoamine oxidase A complexed with clorgyline
Acta Crystallogr. Sect. D
60
317-319
2004
Rattus norvegicus
brenda
Ucar, G.
Substrate specificities of monoamine oxidase isoforms
FABAD J. Pharm. Sci.
27
149-156
2002
Homo sapiens, Rattus norvegicus
-
brenda
Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T.
Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors
J. Mol. Biol.
338
103-114
2004
Rattus norvegicus (P21396)
brenda
Egashira, T.; Takayama, F.; Sakai, K.
Inhibition by Zn2+ of A-form monoamine oxidase in monkey brain mitochondria
J. Pharm. Sci.
91
239-245
2003
Oryctolagus cuniculus, Macaca fuscata, Rattus norvegicus
brenda
Guimaraes, J.T.; Vindis, C.; Soares-da-Silva, P.; Parini, A.
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex
Life Sci.
73
955-967
2003
Rattus norvegicus
brenda
Ucar, G.; Tas, C.; Tuemer, A.
Monoamine oxidase inhibitory activities of the scorpion Mesobuthus gibbosus (Buthidae) venom peptides
Toxicon
45
43-52
2005
Homo sapiens, Rattus norvegicus
brenda
Petrovic, N.; Cvijic, G.; Djordjevic, J.; Davidovic, V.
The activities of antioxidant enzymes and monoamine oxidase and uncoupling protein 1 content in brown fat of hypo- and hyperthyroid rats
Ann. N. Y. Acad. Sci.
1040
431-435
2005
Rattus norvegicus
brenda
Ochiai, Y.; Itoh, K.; Sakurai, E.; Adachi, M.; Tanaka, Y.
Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems
Biol. Pharm. Bull.
29
2362-2366
2006
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E.
Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors
J. Biol. Chem.
280
15761-15766
2005
Equus caballus, Ovis aries, Rattus norvegicus (P19643), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens, Bos taurus (P56560), Bos taurus, Mus musculus (Q8BW75), Mus musculus
brenda
Dar, A.; Khan, K.M.; Ateeq, H.S.; Khan, S.; Rahat, S.; Perveen, S.; Supuran, C.T.
Inhibition of monoamine oxidase-A activity in rat brain by synthetic hydrazines: structure-activity relationship (SAR)
J. Enzyme Inhib. Med. Chem.
20
269-274
2005
Rattus norvegicus (P21396)
brenda
Huh, J.W.; Choi, M.M.; Lee, J.H.; Yang, S.J.; Kim, M.J.; Choi, J.; Lee, K.H.; Lee, J.E.; Cho, S.W.
Activation of monoamine oxidase isotypes by prolonged intake of aluminum in rat brain
J. Inorg. Biochem.
99
2088-2091
2005
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Bertini, V.; Buffoni, F.; Ignesti, G.; Picci, N.; Trombino, S.; Iemma, F.; Alfei, S.; Pocci, M.; Lucchesini, F.; De Munno, A.
Alkylamino derivatives of 4-aminomethylpyridine as inhibitors of copper-containing amine oxidases
J. Med. Chem.
48
664-670
2005
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.D.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A.
Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches
J. Med. Chem.
49
4912-4925
2006
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Palaska, E.; Aydin, F.; Ucar, G.; Erol, D.
Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole derivatives
Arch. Pharm.
341
209-215
2008
Rattus norvegicus (P21396), Homo sapiens (P27338), Homo sapiens
brenda
Upadhyay, A.K.; Wang, J.; Edmondson, D.E.
Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms
Biochemistry
47
526-536
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Kumar, P.; Taha, A.; Sharma, D.; Kale, R.K.; Baquer, N.Z.
Effect of dehydroepiandrosterone (DHEA) on monoamine oxidase activity, lipid peroxidation and lipofuscin accumulation in aging rat brain regions
Biogerontology
9
235-246
2008
Rattus norvegicus
brenda
Guillem, K.; Vouillac, C.; Koob, G.F.; Cador, M.; Stinus, L.
Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion
Biol. Psychiatry
63
158-163
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Gkhan-Kelekci, N.; Yabanoglu, S.; Kepeli, E.; Salgin, U.; zgen, O.; Ucar, G.; Ye?ilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A.
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics
Bioorg. Med. Chem.
15
5775-5786
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Ke, S.; Li, Z.; Qian, X.
1,3,4-Oxadiazole-3(2H)-carboxamide derivatives as potential novel class of monoamine oxidase (MAO) inhibitors: synthesis, evaluation, and role of urea moiety
Bioorg. Med. Chem.
16
7565-7572
2008
Rattus norvegicus
brenda
Aguiar, L.M.; Macedo, D.S.; Vasconcelos, S.M.; Oliveira, A.A.; de Sousa, F.C.; Viana, G.S.
CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats
Brain Res.
1191
192-199
2008
Rattus norvegicus (P19643), Rattus norvegicus, Rattus norvegicus Wistar (P19643)
brenda
Birgner, C.; Kindlundh-Hoegberg, A.M.; Oreland, L.; Alsioe, J.; Lindblom, J.; Schioeth, H.B.; Bergstroem, L.
Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration
Brain Res.
1219
103-110
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Hewton, R.; Salem, A.; Irvine, R.J.
Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor
Clin. Exp. Pharmacol. Physiol.
34
1051-1057
2007
Rattus norvegicus (P21396)
brenda
Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.
Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target
Curr. Med. Chem.
15
1827-1839
2008
Rattus norvegicus, Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Izumi, T.; Iwamoto, N.; Kitaichi, Y.; Kato, A.; Inoue, T.; Koyama, T.
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats
Eur. J. Pharmacol.
565
105-112
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Savitha, S.; Naveen, B.; Panneerselvam, C.
Carnitine and lipoate ameliorates lipofuscin accumulation and monoamine oxidase activity in aged rat heart
Eur. J. Pharmacol.
574
61-65
2007
Rattus norvegicus
brenda
Olsen, H.T.; Stafford, G.I.; van Staden, J.; Christensen, S.B.; Jaeger, A.K.
Isolation of the MAO-inhibitor naringenin from Mentha aquatica L
J. Ethnopharmacol.
117
500-502
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Carotti, A.; Catto, M.; Leonetti, F.; Campagna, F.; Soto-Otero, R.; Mendez-Alvarez, E.; Thull, U.; Testa, B.; Altomare, C.
Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives
J. Med. Chem.
50
5364-5371
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Sunal, S.G.; Yabanoglu, S.; Yesilada, A.; Ucar, G.
Monoamine oxidase inhibitory activities of novel 3,4-dihydroquinolin-(1H)-2-one derivatives
J. Neural Transm.
114
717-719
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Wang, J.; Edmondson, D.E.
Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-As
J. Neural Transm.
114
721-724
2007
Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens
brenda
Finberg, J.P.; Sader-Mazbar, O.
Modification of L-DOPA pharmacological activity by MAO inhibitors
J. Neural Transm.
114
801-805
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Speiser, Z.; Fine, T.; Litinetsky, L.; Eliash, S.; Blaugrund, E.; Cohen, S.
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline
J. Neural Transm.
115
107-116
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Ramadan, Z.B.; Wrang, M.L.; Tipton, K.F.
Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide
Neurochem. Res.
32
1783-1790
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Bos taurus (P56560)
brenda
MacKenzie, E.M.; Grant, S.L.; Baker, G.B.; Wood, P.L.
Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition
Neurochem. Res.
33
430-436
2008
Rattus norvegicus
brenda
Carpene, C.; Iffiu-Soltesz, Z.; Bour, S.; Prevot, D.; Valet, P.
Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats
Pharmacol. Res.
56
522-530
2007
Rattus norvegicus
brenda
Prevot, D.; Soltesz, Z.; Abello, V.; Wanecq, E.; Valet, P.; Unzeta, M.; Carpene, C.
Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats
Pharmacol. Res.
56
70-79
2007
Rattus norvegicus
brenda
Carpene, C.; Abello, V.; Iffiu-Soltesz, Z.; Mercier, N.; Feve, B.; Valet, P.
Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors
Pharmacol. Res.
57
426-434
2008
Rattus norvegicus
brenda
Upadhyay, A.K.; Edmondson, D.E.
Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris
Protein Expr. Purif.
59
349-356
2008
Rattus norvegicus (P19643)
brenda
Franke, R.M.; Belluzzi, J.D.; Leslie, F.M.
Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats
Psychopharmacology
195
117-124
2007
Rattus norvegicus
brenda
Halberstadt, A.L.; Buell, M.R.; Masten, V.L.; Risbrough, V.B.; Geyer, M.A.
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
Psychopharmacology
201
55-66
2008
Rattus norvegicus (P21396)
brenda
Osman, M.Y.; Osman, H.M.
Inhibitory effect of acetylcholine on monoamine oxidase A and B activity in different parts of rat brain
Arzneimittelforschung
58
493-496
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Upadhyay, A.K.; Borbat, P.P.; Wang, J.; Freed, J.H.; Edmondson, D.E.
Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy
Biochemistry
47
1554-1566
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
MacKenzie, E.M.; Fassihi, A.; Davood, A.; Chen, Q.H.; Rauw, G.; Rauw, G.; Knaus, E.E.; Baker, G.B.
N-Propynyl analogs of beta-phenylethylidenehydrazines: synthesis and evaluation of effects on glycine, GABA, and monoamine oxidase
Bioorg. Med. Chem.
16
8254-8263
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21936)
brenda
Vilches-Herrera, M.; Miranda-Sepulveda, J.; Rebolledo-Fuentes, M.; Fierro, A.; Luehr, S.; Iturriaga-Vasquez, P.; Cassels, B.K.; Reyes-Parada, M.
Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors
Bioorg. Med. Chem.
17
2452-2460
2009
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Perez-Neri, I.; Montes, S.; Rios, C.
Inhibitory effect of dehydroepiandrosterone on brain monoamine oxidase activity: in vivo and in vitro studies
Life Sci.
85
652-656
2009
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Rattus norvegicus
brenda
Wang, J.; Edmondson, D.E.
High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: comparison with human MAO A
Protein Expr. Purif.
70
211-217
2009
Rattus norvegicus, Rattus norvegicus (P21396)
brenda
Iagodina, O.
Comparative study of catalytic properties of mink and rat liver monoamine oxidase
Zh. Evol. Biokhim. Fiziol.
44
570-576
2008
Rattus norvegicus, Neogale vison
brenda
Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A.
Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases
Biochemistry
48
4220-4230
2009
Bos taurus, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Goekhan-Kelekci, N.; Simsek, O.O.; Ercan, A.; Yelekci, K.; Sahin, Z.S.; I?ik, S.; Ucar, G.; Bilgin, A.A.
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors
Bioorg. Med. Chem.
17
6761-6772
2009
Rattus norvegicus
brenda
Luehr, S.; Vilches-Herrera, M.; Fierro, A.; Ramsay, R.R.; Edmondson, D.E.; Reyes-Parada, M.; Cassels, B.K.; Iturriaga-Vasquez, P.
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
1388-1395
2010
Homo sapiens, Rattus norvegicus
brenda
Shi, L.; Yang, Y.; Li, Z.L.; Zhu, Z.W.; Liu, C.H.; Zhu, H.L.
Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors
Bioorg. Med. Chem.
18
1659-1664
2010
Rattus norvegicus (P21396)
brenda
Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A.
Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, revers
J. Med. Chem.
52
6685-6706
2009
Rattus norvegicus
brenda
Wang, J.; Edmondson, D.E.
2H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme
Biochemistry
50
7710-7717
2011
Rattus norvegicus
brenda
Pisani, L.; Barletta, M.; Soto-Otero, R.; Nicolotti, O.; Mendez-Alvarez, E.; Catto, M.; Introcaso, A.; Stefanachi, A.; Cellamare, S.; Altomare, C.; Carotti, A.
Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors
J. Med. Chem.
56
2651-2664
2013
Rattus norvegicus
brenda
Sergutina, A.V.; Rakhmanova, V.I.
Differences in monoamine oxidase activity in the brain of Wistar and August rats with high and low locomotor activity a cytochemical study
Bull. Exp. Biol. Med.
161
211-214
2016
Rattus norvegicus
brenda
Koc, G.?.; Tan, O.U.; Ucar, G.; Yildirim, E.; Erol, K.; Palaska, E.
Synthesis and monoamine oxidase inhibitory activities of some 3-(4-fluorophenyl)-5-aryl-n-substituted-4,5-dihydro-(1H)-pyrazole-1-carbothioamide derivatives
Drug Res.
64
591-598
2014
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
brenda
Tzvetkov, N.T.; Stammler, H.G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M.
Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors
Eur. J. Med. Chem.
127
470-492
2017
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Sampaio, T.B.; Da Rocha, J.T.; Prigol, M.; Saraiva, R.A.; Nogara, P.F.; Stein, A.L.; da Rocha, J.B.; Zeni, G.; Nogueira, C.W.
4-Organoseleno-isoquinolines selectively and reversibly inhibit the cerebral monoamine oxidase B activity
J. Mol. Neurosci.
59
135-145
2016
Rattus norvegicus (P19643)
brenda
Yang, D.; Wang, R.; Zhu, J.; Cao, Q.; Qin, J.; Zhu, H.; Qian, S.
Synthesis, crystal structures, molecular docking, vitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid
J. Mol. Struct.
1128
493-498
2017
Rattus norvegicus (P19643), Homo sapiens (P27338)
-
brenda